MedTrace Logo

Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

NCT02585401 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 99

Last updated 2017-03-21

No results posted yet for this study

Summary

The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.

Conditions

  • Age-related Macular Degeneration (AMD)
  • Central Retinal Vein Occlusion (CRVO)
  • Diabetic Macular Edema (DME)

Interventions

DRUG

Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

The physician questionnaire will contain primarily closed-ended questions (e.g., multiple choice, true/false), with few free-text response fields, eliciting responses measuring physician knowledge and understanding of the key information in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-18
Primary Completion
2016-03-31
Completion
2016-05-19

Countries

  • Canada

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02585401 on ClinicalTrials.gov